Welcome to our dedicated page for Aslan Pharms news (Ticker: ASLN), a resource for investors and traders seeking the latest updates and insights on Aslan Pharms stock.
ASLAN Pharmaceuticals (ASLN) is a clinical-stage biopharmaceutical company advancing novel therapies for immunology and oncology conditions. This news hub provides investors and researchers with timely updates on clinical developments, strategic partnerships, and regulatory milestones.
Access verified information about ASLAN’s pipeline progress, including updates on eblasakimab (atopic dermatitis) and farudodstat (cancer metabolic pathways). Our curated collection features press releases, clinical trial results, and collaboration announcements with industry leaders like Bristol-Myers Squibb and CSL.
Key focus areas include advancements in immune checkpoint research, Asia-Pacific clinical programs, and orphan drug designations. Content is organized to help users track regulatory submissions, patent developments, and scientific conference presentations.
Bookmark this page for streamlined access to ASLAN’s latest innovations in targeted biologics and small molecule therapies. Check regularly for objective reporting on Phase I-III trial outcomes and partnership-driven research initiatives.
ASLAN Pharmaceuticals (NASDAQ: ASLN) announced acceptance of two late-breaking abstracts for the 1st International Societies for Investigative Dermatology (ISID) Meeting in Tokyo from May 10-13, 2023. One abstract focuses on eblasakimab and its effects in atopic dermatitis (AD), while the other highlights farudodstat in alopecia areata. Published data show that eblasakimab significantly improves Eczema Area and Severity Index (EASI) scores, particularly in sensitive areas. The treatment also inhibits neuronal sensitization to itch, potentially offering broad therapeutic benefits. Results from the Phase 2 TREK-AD study are expected in early July 2023, while an upcoming proof-of-concept trial for farudodstat is planned for Q2 2023.
ASLAN Pharmaceuticals (Nasdaq: ASLN) announced that it has regained compliance with Nasdaq's minimum bid price requirement, with a closing bid price above $1.00 for 10 consecutive business days, as of March 27, 2023. This follows a previous notice from Nasdaq on March 28, 2022, regarding non-compliance due to the bid price dropping below $1.00. The company develops innovative treatments, including eblasakimab for atopic dermatitis and farudodstat for alopecia areata, with ongoing clinical trials. ASLN's continued listing on Nasdaq is contingent upon meeting all applicable standards moving forward.
ASLAN Pharmaceuticals (Nasdaq: ASLN) has announced its financial results for Q4 and full year 2022, reporting a net loss of $51.4 million compared to $31.3 million in 2021. The increase in loss is primarily due to elevated research and development expenses of $38.0 million, driven by clinical development costs for eblasakimab. The company has successfully enrolled patients in its TREK-AD Phase 2b trial and expects topline data by early July 2023. Following a recent $20 million financing, ASLAN anticipates its cash runway extended through Q2 2024. Additionally, a Phase 2 trial for farudodstat in alopecia areata is set to begin in Q2 2023, with data expected in Q1 2024.
FAQ
What is the current stock price of Aslan Pharms (ASLN)?
What is the market cap of Aslan Pharms (ASLN)?
